Antipsychotic trials in schizophrenia
Subtitle: the CATIE project
By: edited by T. Scott Stroup, Jeffrey A. Lieberman
Series: Cambridge medicine; Cambridge medicine
Publisher: Cambridge University Press
Published: 2010
Place of publication: Cambridge, UK; New York
Language: eng
Number of pages: 312
ISBN-13: 9780521895330
Description: "Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading"--Provided by publisher.
Notes: Includes bibliographical references and index.
Table of contents: title: Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index.